Ed Reznik, Ph.D.
Affiliations: | 2013 | Biomedical Engineering | Boston University, Boston, MA, United States |
Area:
Biomedical Engineering, Applied MathematicsGoogle:
"Ed Reznik"Parents
Sign in to add mentor| Daniel Segrè | grad student | 2013 | Boston University (Microtree) | |
| (The dynamics of metabolic regulation.) | ||||
| Chris Sander | post-doc | (Computational Biology Tree) | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mahmood M, Liu EM, Shergold AL, et al. (2024) Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma. Nature Cancer |
| Benedetti E, Liu EM, Tang C, et al. (2023) A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation. Nature Metabolism |
| Mahmood M, Liu EM, Shergold AL, et al. (2023) Tumour mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade. Biorxiv : the Preprint Server For Biology |
| Kim M, Mahmood M, Reznik E, et al. (2022) Mitochondrial DNA is a major source of driver mutations in cancer. Trends in Cancer |
| Hakimi AA, Attalla K, DiNatale RG, et al. (2020) A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications. 11: 4168 |
| Gorelick AN, Sánchez-Rivera FJ, Cai Y, et al. (2020) Phase and context shape the function of composite oncogenic mutations. Nature |
| Marcon J, DiNatale RG, Sanchez A, et al. (2020) Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy number variations as drivers of disease progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Vasan N, Razavi P, Johnson JL, et al. (2020) Abstract P3-03-01: Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer Cancer Research. 80 |
| DiNatale RG, Gorelick AN, Makarov V, et al. (2019) Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus |
| DiNatale RG, Xie W, Becerra MF, et al. (2019) The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology |